|
RESprotect History at a Glance |
| 2000 |
RESprotect founded as a Fraunhofer-Society spin-off. |
| 2001 |
Start of the development of RP101 as a cancer
therapeutic. |
| 2002 |
Start of the development of next generation product
candidates. |
| 2004 |
Excellent results in a clinical pilot study led to out-licensing of the North-American rights of the company's first drug RP101 to Avantogen Ltd./Los Angeles. |
| 2007 |
Excellent results in a second clinical study led to transfer of the North-American rights of RP101 to SciClone Pharmaceuticals, USA |
| 2008 |
Out-licensing of the Korean rights of RP101 to Kwang Dong Pharmaceuticals/Seoul, South Korea. |
| 2007-2009 |
Phase II double blind study with pancreatic cancer patients. |
| 2008 |
Hsp27 confirmed as the novel and unique target of RP101. |
| 2010 |
Orphan Drug status for RP101, SME status for RESprotect. |
| 2011 |
RESprotect received back the North-America rights for RP101 from SciClone Pharmaceuticals and is currently aiming for strategic partnerships to develop and market RP101 and its next generation product candidates on a worldwide basis. |
|